Introduction. The National External Quality Assessment Scheme (NEQAS) has been established by the Department of Health-Philippines (DOH) to provide DOH-approved external quality assessment programs, including the Proficiency Test (PT) for Bacteriology to clinical laboratories. The PT for Bacteriology aims to monitor and evaluate laboratory capabilities in the identification of clinically important pathogens through proficiency testing. Since then, participation in the NEQAS has been a requirement for clinical laboratories to obtain a license to operate from the DOH-Health Facilities and Services Regulatory Bureau (HFSRB).
INTRODUCTION
Clinical bacteriology laboratories carry out the detection and isolation of bacterial pathogens for management and surveillance of infectious diseases. They are responsible for detecting antibiotic resistance, identifying outbreak pathogens, and communicating incidences and information concerning infectious diseases to public health authorities. These important tasks are the reason that high quality testing, and accurate and precise results must always be ensured. 1 The Proficiency Test (PT) for Bacteriology assesses the ability of clinical microbiology laboratories to identify and characterize clinically important bacteria and conduct antimicrobial susceptibility tests. It aims to improve the performances of laboratories and ensure high quality and reliable testing in the field of clinical bacteriology. 2, 3 In other countries, external quality assessment schemes (EQAS) and PTs for clinical microbiology, The Department Administrative Order No. 2007-0027 and Memorandum No. 2009-0086, were then issued by the DOH, which required every clinical laboratory throughout the country to participate in the National External Quality Assessment Schemes (NEQAS) in order to obtain a license to operate (LTO) from the DOH Health Facilities and Services Regulatory Bureau (HFSRB, formerly Bureau of Health Facilities and Services).
11,12 NEQAS issues DOH-approved external quality assessment programs for bacteriology, parasitology, and mycobacteriology to clinical laboratories by providing a proficiency test that aims to monitor and evaluate the laboratory's capabilities to identify clinically important pathogens. Thus, the RITM-NRL has been providing annual PTs for bacteriology under the NEQAS for Bacteriology, Parasitology, and Mycobacteriology to clinical laboratories since 2009. This report summarizes and examines the results of the PT for Bacteriology from 2009 to 2015 and the performances of participating clinical laboratories. The information and analysis were only limited to the scores, regional location, ownership type and accreditation category of 468 participants in the PT throughout the seven-year period and to the data acquired from the assessments of selected participating laboratories.
METHODOLOGY Baseline assessment of laboratories
A baseline on-site assessment of tertiary clinical laboratories throughout the country was conducted by RITM-NRL in 2008. The assessment aimed to (1) monitor their compliance with the minimum and essential requirements as set by RITM-NRL (Table 1) ; (2) evaluate their capacity to isolate, identify, and characterize medically important bacterial pathogens; (3) identify their deficiencies, which may result to poor performance in bacteriological testing; (4) educate laboratorians on current microbiological advancements; (5) and promote good laboratory practices. The list of tertiary laboratories provided by HFSRB served as the basis for the number of laboratories to be assessed. The assessment covered laboratory practices on specimen processing: (1) isolation and identification of medically important bacteria; (2) methods for antimicrobial susceptibility testing; (3) internal and external quality assessment practices; (4) use of functional equipment, instruments, culture media, reagents, kits, glassware, and disposables; and (5) waste management. 
Materials and analyte preparation
Analyte culture, inoculation, and verification Clinically-significant bacteria were subcultured from stock cultures in skim milk-tryptone-glucose-glycerol (STGG) media 14 incubated at 36±1°C for 18 to 24 hours. Cultures were examined for purity; assayed through conventional identification methods 15 and commercial identification testing systems: API® (bioMérieux, Marcy-l'Étoile, France) and VITEK® 2 (bioMérieux, Marcyl'Étoile, France); and compared to ATCC® biological standards (ATCC, Manassas, Virginia, USA) to verify their identities ( Table 2 ). The analytes were inoculated in semi-solid sheep blood agar (SBA) 16 contained in 2 mL-cryogenic vials (Corning Inc., Corning, New York, USA) and incubated at 36±1°C for 18 to 24 hours prior to transport.
Verification of analyte antimicrobial susceptibility
Antimicrobial susceptibility of analytes was verified using BBL™ Sensi-Disc™ Susceptibility Test Discs (Becton, Dickinson, and Co., Sparks, Maryland, USA). The panel of antibiotics used was based on the Performance Standards for Antimicrobial Susceptibility Testing of the Clinical and Laboratory Standards Institute (CLSI, Wayne, Pennsylvania, USA).
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Packaging
Analytes sent to participating laboratories were packaged in accordance to the international standard of transporting biohazard materials. 18, 19 Each vial was sealed with Parafilm M® (Bemis Co. Inc., Oshkosh, Wisconsin, USA), individually wrapped in a paper towel, and placed inside a 100 mm × 150 mm resealable polypropylene resin bags along with other analytes. The wrapped vials were then encased in 600 mL polypropylene canister (Philtop Industries Inc., Valenzuela City, Metro Manila, Philippines) and placed inside a 120 mm × 115 mm × 190 mm corrugated box (Thousand Oaks Packaging Corp., Parañaque City, Metro Manila, Philippines) with the necessary attachments and labels. The package also includes standard proficiency testing guidelines that contain basic information and instructions needed for the handling of the analytes and an answer sheet.
Quality Control of Transport Media and Packaged Analytes
The semi-solid sheep blood agar (SSBA) to be used as transport media was assured for sterility and tested for culture response before use in the PT. Four sets of cultures of each of all the organisms used as analytes in the PT were prepared and each set was subjected to each of the four different treatments. For the first treatment, separate packages containing one set of different analytes were sent to random locations of participating laboratories throughout the country. The selected laboratories were asked to return the sealed package to RITM. Upon return, the analytes were examined for contamination by unwanted organisms and tested for viability through routine culture examination. For the remaining treatments, three sets were incubated at 36±1ºC, 4±2 ºC, and ambient temperature, respectively. Growth was observed after three, five, and seven days. After seven days of incubation, the analytes were subcultured and re-identified through conventional methods and commercial identification systems such as API® and VITEK® 2.
The Bacteriology PT program
Participating laboratories were asked to identify each of the three analytes by means of their routine methods or standard operating procedures. They were also required to perform antimicrobial susceptibility testing on one pre-assigned analyte using the panel of antibiotics recommended by CLSI. After receiving the analytes, participants were given fifteen working days to complete the PT.
The Overall Score, with a perfect rating of 100%, comprised of 75% for organism identification and 25% for AST. RITM-NRL set the passing score to be 80%. A correct identification-with correct binomial name-amounts to 25 points; an acceptable identification-with correct genus but incorrect or unspecified species-amounts to 10 points; an incorrect one amounts to no point. A correct report of antibiotic susceptibility amounts to one point while an incorrect report amounts to no point. The identification of an additional organism would result into an addition to the number of principal organisms in the equation but no addition to the points corresponding to the correct and acceptable identification. This would eventually lead to the reduction of the overall score. The following equation represents the computation for the overall score:
Each of the participating laboratories who had accomplished the PT and submitted their answers to NEQAS received a certificate of participation, a summary of results of its PT performance, and a learning monograph, which recommends standard methods of identifying the analytes and performing AST.
Evaluation of the overall performance of laboratories
Participating laboratories were grouped according to the number of times they enrolled in the annual PTs from 2009 to 2015 and the number of times they got a passing score of 80%. The performances of participating laboratories were classified as "good', "fair", and "poor" based on the number of times they passed the annual PT. "Poor performers" refers to participating laboratories who had not met the 80% passing rate for more than 50% of their annual PT participation. "Fair performers" refers to participating laboratories who had met the passing rate in 50% of their annual PT participation. Finally, "good performers" refers to participating laboratories who had passed more than 50% of their annual PT participation.
Assessment of poor performing laboratories
Participating government laboratories that had been consistently obtaining scores below 80% in the 2009-2012 PTs were selected for an on-site reassessment in 2013. Details on the updated training of laboratory personnel; availability of laboratory equipment, reagents, culture media, antibiotics, and glassware; reliance on automated and/or semi-automated systems for identification before use in the PT. Four sets of cultures of each of all the organisms used as analytes in the PT were prepared and each set was subjected to each of the four different treatments. For the first treatment, separate packages containing one set of different analytes were sent to random locations of participating laboratories throughout the country. The selected laboratories were asked to return the sealed package to RITM. Upon return, the analytes were examined for contamination by unwanted organisms and tested for viability through routine culture examination. For the remaining treatments, three sets were incubated at 36±1ºC, 4±2 ºC, and ambient temperature, respectively. Growth was observed after three, five, and seven days. After seven days of incubation, the analytes were subcultured and reidentified through conventional methods and commercial identification systems such as API® and VITEK® 2.
The Bacteriology PT program
Evaluation of the overall performance of laboratories
Participating laboratories were grouped according to the number of times they enrolled in the annual PTs from 2009 to 2015 and the number of times they got a passing score of 80%. The performances of participating laboratories were classified as -good', -fair‖, and -poor‖ based on the number of times they passed the annual PT. -Poor performers‖ refers to participating laboratories who had not met the 80% passing rate for more than 50% of their annual PT participation. -Fair performers‖ refers to participating laboratories who had met the passing rate in 50% of their annual PT participation. Finally, -good performers‖ refers to participating laboratories who had passed more than 50% of their annual PT participation.
Assessment of poor performing laboratories
http://philippinejournalofpathology.org | Vol. (Table 1) . One hundred eighteen (25.2% of 468) laboratories, on the contrary, never got a passing score in all the PTs, in which they enrolled. Overall, poor performers comprise the most number (60.0%, 281/468) of participating laboratories (Figure 3) . A proportion of 40.2% (35/87) government laboratories and 70.4% (247/381) of privately owned laboratories performed poorly in the PT over the seven-year period. While the overall number of participating laboratories and the number of passers were increasing, majority of participating laboratories performed poorly in the PT over the seven years. Participation in EQA programs has been proven to improve a laboratory in many ways. It allows the participants to have an idea of their capability and monitor continual improvement, since it generates information that can be used to assess the overall competence and needs of participants. 24 It also brings benefits and challenges to the participants, aside from meeting regulatory requirements. 1 The improvement in the performance of bacteriology laboratories in the Philippines in the Proficiency Test provided by NEQAS is comparable to the improvement of laboratories that participated in different EQAS/PT in other countries. In the 1982-1999 Tokyo Metropolitan Government External Quality Assessment Program, an improvement in the performance of independent laboratories in Tokyo, Japan regarding the identification of H. influenzae, MRSA, and some pathogenic enteric bacteria was observed. 6 In the 1992-1996 Swiss External Quality Assessment Scheme in Bacteriology and Mycology, the increasing mean scores of all participants and the number of participating laboratories with high average scores over the four year period reflected the improving performances of participating laboratories. 7 In the United States, the Clinical Laboratory Improvement Amendments of 1988 (CLIA'88) mandate universal requirements for all clinical laboratory-testing sites. This mandate includes the provision of PT that defines laboratory performance. Through PT as one of its tool, CLIA has ensured the adherence of participating laboratories to good clinical practices and improvement in the quality of laboratory tests since 1994. 25 External quality assessment programs are recognized as an effective tool in improving the quality of medical laboratories in Europe. 26 Further improvements are being considered to their existing EQA programs such as accreditation of schemes and further integration to information technology 27 that can also be applied in the Philippines. and it protects cells from degradation; however, the subsequent processes of reconstitution and multiple passages do not demonstrate clinical relevance and realism. It completely lacks resemblance to clinical specimens. 4 Furthermore, artificial handling and significant matrix effects can affect the growth, colony morphology, and nutrient metabolism of organisms, thus affecting proper identification and characterization of analytes. 28 In this PT, the use of semi-solid SBA as matrix was proven to be effective in ensuring the viability of organisms during transport, through quality control. All of the isolates sent for quality control throughout 2009 to 2015 were observed to be contaminant-free and viable.
Identification and AST
Bacteriology laboratories in the Philippines used conventional methods, manual commercial kits, and automated systems for the characterization and identification of clinically significant pathogens. The organisms identified with least difficulty were E. coli, S. aureus, MRSA, C. albicans, S. enterica sv. Typhi, and P. aeruginosa. In contrast, the six organisms identified with highest difficulty were A. lwoffii, C. tropicalis, M. catarrhalis, E. aerogenes, H. influenzae, and S. pneumoniae (Table 2) . Additionally, the antibiotic susceptibilities of S. pneumoniae, E. cloacae, and H. influenzae were the most difficult to determine (Table 3) .
The organisms identified with least difficulty are usually distinguished with colony examination and few straightforward biochemical tests. S. aureus is identified as Gram-positive coccus, which is positive for catalase and coagulase tests. Salmonella enterica sv. Typhi can be distinguished from nontyphoidal Salmonella with its distinct biochemical characteristics: it is citrate-negative, ornithine-negative, and mucate-negative; it yields alkaline products on aerobic environment, acidic products on anaerobic environment; and it weakly produces hydrogen sulfide gas in triple sugar iron (TSI) agar. Moreover, S. enterica sv. Typhi can be differentiated from other Salmonella serotypes through serological tests based on the antigenic properties of the somatic (O:9), flagellar (H-d), and capsular (Vi) antigens. The identity of the yeast, C. albicans, can be confirmed when it produces germ tube during germination in horse serum at 37°C, and terminal chlamydospores on hyphae or pseudohyphae during growth in corn meal agar at 25°C. E. coli and P. aeruginosa can be identified through examination of colony morphology in MacConkey agar and a few basic biochemical tests. 15 Some of the organisms identified with highest difficulty, A. lwoffii and M. catarrhalis, are nonfermentative Gram-negative bacteria that belong to the Moraxellaceae family. Acinetobacter species are oxidase-negative, catalase-positive, indole-negative coccobacillary bacteria. A. lwoffii can be differentiated from other Acinetobacter species through carbon assimilation tests. 15 Moraxella species, on the other hand, are oxidase-positive, catalase-positive, indole-negative coccoid or coccobacillary bacteria. They can be differentiated from the similarly oxidase-positive and catalasepositive Neisseria species through examination of the colonies in agar: Moraxella colonies may be pushed intact across the plate with a loop like a hockey puck; or through DNase and tributyrin tests. M. catarrhalis can be distinguished from other Moraxella species through its ability to reduce nitrate and nitrite and its inability to alkalinize acetate and acidify ethylene glycol. Enterobacter species belong to the Enterobacteriaceae family. E. aerogenes can be differentiated from other Enterobacter species through lysine decarboxylase, arginine dihydrolase, ornithine decarboxylase, and carbohydrate fermentation tests. 15 C. tropicalis, a non-albicans Candida (NAC) yeast species, 29 is germ tube-negative. It can be distinguished from other Candida species through microscopic examination of morphological features of the yeast on cornmeal agar; through carbohydrate assimilation tests; and through carbohydrate fermentation tests. 15 In the 2008 assessment, majority (66.7%, 231/347) of the laboratories assessed used human blood agar in the isolation, detection, and characterization of clinically important bacterial pathogens. These pathogens, especially fastidious organisms such as S. pneumoniae and H. influenzae, are less likely to be detected when using human blood agar for culture since antibodies and residual antibiotics in human blood may inhibit the growth of bacterial isolates. It will also result to pathogens producing incorrect or varying hemolysis on the blood plate agar which is one of the characteristics critical when identifying a microorganism. Instead, trypticase soy agar plate with 5% defibrinated sheep, goat, rabbit, or horse blood is recommended for the preparation of blood agar plate and as primary culture plate media for bacterial pathogens. 23 Streptococcus pneumoniae and H. influenzae are fastidious organisms, which grow best at 36±1°C with around 5%-10% carbon dioxide or in a candle jar. S. pneumoniae can be differentiated from other streptococci through characterization of colonies on blood agar plates; optochin test; and bile solubility test using sodium deoxycholate. H. influenzae, on the other hand, requires hemin (X factor) and nicotinamide adenine dinucleotide (V factor) for growth; thus, the chocolate agar plate, which contains both factors, is used as the standard growth medium. 15, 23 In addition, S. pneumoniae and H. influenzae must be grown in Mueller-Hinton agar (MHA) supplemented with additional growth factors for AST. MHA with 5% sheep blood is the medium required for AST of S. pneumoniae by disk diffusion. Plates must be incubated at 35±2°C with 5% CO2 for 20-24 hours. Haemophilus test medium (HTM; comprised of MHA plus hematin, nicotinamide adenine dinucleotide, and yeast extract) is required for the AST of H. influenzae by disk diffusion, and plates must be incubated at 36±1°C with 5%-10% CO2 for 16-18 hours. 17 Organisms that are difficult to identify require additional tests, equipment, media, supplements, and reagents. Failure to identify organisms that require more complex bacteriological testing can be attributed to the large proportion of laboratories lacking minimum and required essential media and reagents, such as sugars for carbohydrate utilization tests and amino acids for amino acid metabolism tests, based on the result of the 2008 assessment. Also, failure to determine the correct antibiotic susceptibility of bacteria through disk diffusion can be attributed to the large proportion of laboratories that were not using the latest edition of the Performance Standards for Antimicrobial Susceptibility Testing by the CLSI in 2008. Laboratories are expected to correctly interpret the zone diameter breakpoints in disk diffusion according to the updated CLSI standards. Moreover, accurate AST results cannot be achieved with the lack of antibiotics, media (e.g. MHA, etc.), supplements (e.g. nonhuman mammalian blood, hematin, etc.), and equipment (e.g. CO2 incubators or candle jars, etc.).
Assessment of poor performing government laboratories for bacteriology
Only 31 government-owned laboratories that performed poorly in the 2009-2012 PTs were assessed. Two (6.5% of 31) were found to be non-functional due to a lack of budget. Only 12.9% (4/31) of the laboratories had personnel with updated training; 45.2% (14/31) used ATCC biological standards for quality control; and only 29.0% (9/31) implemented SOPs and quality control of culture media, antibiotics, and equipment. Only 9.7% (3/31) had complete essential equipment; 9.7% (3/31) had complete essential culture media and antibiotics for AST; and none (0/31) of the laboratories had complete essential reagents. On the other hand, 83.9% (26/31) had complete essential glassware. Overall, majority of the assessed laboratories did not meet the minimum and essential requirements, except for having complete essential glassware.
Thirteen (41.9% of 31) laboratories use automated and semiautomated equipment. Six laboratories (19.4% of 31) were using VITEK® 2; four (12.9% of 31) were using API® identification testing kits; and three (9.7% of 31) were using BBL™ Crystal™ Identification Systems (Becton, Dickinson and Co. Diagnostic Systems, Sparks, Maryland, USA). Automated and semiautomated systems require freshly grown isolates within 24 hours as its test template; hence, laboratorians still need the basic materials, equipment, and skills to culture and isolate medically important bacteria and fungi. Laboratorians also need to check the viability and density measurement of the organisms to be tested for AST since automated systems which conducts its AST based on broth microdilution testing method, generally require more than 105 viable cells. 30 Moreover, failure to assign an identification to an organism as a result of low discrimination and discordant identifications by automated and semi-automated systems, still warrants supplemental and confirmatory testing by conventional methods, 31 which require the necessary materials included in the minimum and essential requirements for bacteriological testing.
The baseline assessment of the 347 tertiary laboratories conducted in 2008 and the assessment of 31 poorly performing government laboratories conducted in 2013 found almost similar findings: poor performance was due to poor compliance to the recommended minimum and essential requirements set by RITM-NRL. Both assessments had recommended poor performing laboratories retraining of laboratory personnel; acquisition of the unavailable media, supplements, reagents, and instruments; management on quality control procedures for media, reagents, antibiotics, and stains; use of the current CLSI standards for AST; and review of skills for bacteria culture, isolation and detection.
More actions are still needed to have a better idea of the current state of clinical bacteriological testing in the country and how it affects the results that are being produced. A wider reassessment, that will aim to include all of the participating laboratories, needs to be carried out urgently and regularly in order to identify factors that lead to poor performance and, likewise, ensure high quality testing and accurate reporting of results. Other information can also be acquired during the reassessment such as compliance or deficiencies in skills, training, resources, and implementation of quality assurance procedures. Further data on the methods used (conventional, commercial or semi-/fully automated system) and how it affects the performance of the laboratory can be investigated. The NEQAS program was established to improve the capacity of participating laboratories in producing quality results. This will lead to the elevation of the state of clinical bacteriology in the country and produce quality service for the Filipino people. In aid of this vision, the RITM together with the DOH offers trainings and assistance that can help the participating laboratories in reaching this goal. Other ideas can be explored to attain this goal such as creating a network among the laboratories that may enable them to share knowledge and resources to improve each other's performance and capabilities. The data that will be gathered in the following years and succeeding plans will be included in future reports and studies.
CONCLUSION
An increasing number of participating laboratories had participated in the PT for Bacteriology and the performances of those consistently enrolled had generally improved over 2009-2015. Moreover, a comparison between distributions of scores over the seven-year period has shown an increase in the number of participating laboratories obtaining high to perfect scores. This progress demonstrates that the NEQAS for Bacteriology had improved the quality and reliability of their methods in identifying bacterial pathogens and detecting antibiotic resistance.
In contrast, the large portion of poorly performing laboratories needs to be addressed. The baseline assessment in 2008 and assessment of poor performers in 2013 identified the deficiencies of clinical microbiology laboratories in skills, training, resources, and implementation of quality assurance procedures. A nationwide reassessment of participating laboratories needs to be carried out urgently and regularly in order to identify factors that lead to poor performance and, likewise, ensure high quality testing and accurate reporting of results.
